宣肺止嗽合剂治疗稳定期慢性阻塞性肺疾病的多中心真实世界回顾性研究  

Clinical Observation of Xuanfei Zhisou Mixture(宣肺止嗽合剂)for Stable COPD:A Retrospective Multicenter Real-World Study

作　　者：许大庆[1] 黄燕 贺思云[3] 高元元 梁爱武[5] 顾问[6] 王韶华 张会娟 宋月红 严智林 宋敏平 吕霞 XU Daqing;HUANG YAN;HE Siyun;GAO Yuanyuan;LIANG Aiwu;GU Wen;WANG Shaohua;ZHANG Huijuan;SONG Yuehong;YAN Zhilin;SONG Minping;LYU Xia(Pharmacy Department of The First People′s Hospital of Yinchuan,Yinchuan 750003,China;Pulmonary Disease Department of Inner Mongolia Autonomous Region TCM Hospital,Huhhot 010010,Inner Mongolia,China;Respiratory Department of The Second People′s Hospital of Lanzhou,Lanzhou 730030,Gansu,China;Pulmonary Disease Department of TCM Hospital of Tai County,Taixian 730799,Gansu,China;Respiratory Medicine Department of Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530011,Guangxi,China;Respiratory Medicine Department of Xinhua Hospital Affiliated to Medical College of Shanghai Jiaotong University,Shanghai 200092,China;Respiratory and Digestive Medicine Department of Beijing Integrated Traditional Chinese and Western Medicine Hospital,Beijing 100038,China;Respiratory Medicine Department of Civil Aviation General Hospital,Beijing 100123,China;Gansu Pu′an Pharmaceutical Co.,Ltd,Wuwei 733006,Gansu,China;Beijing Kangyitang Institute of Traditional Chinese Medicine,Beijing 100070,China;Beijing Kangzhong Times Medical Research and Development Co.,Ltd,Beijing 100073,China)

机构地区：[1]银川市第一人民医院药学部,宁夏银川750003 [2]内蒙古自治区中医医院肺病科,内蒙古呼和浩特010010 [3]兰州市第二人民医院呼吸科,甘肃兰州730030 [4]泰县中医医院肺病科,甘肃泰县730799 [5]广西中医药大学附属瑞康医院呼吸内科,广西南宁530011 [6]上海交通大学医学院附属新华医院呼吸内科,上海200092 [7]北京市中西医结合医院呼吸消化内科,北京100038 [8]民航总医院呼吸内科,北京100123 [9]甘肃普安制药股份有限公司,甘肃武威733006 [10]北京康义堂中医研究院,北京100070 [11]北京康众时代医学研究发展有限公司,北京100073

出　　处：《辽宁中医杂志》2024年第7期108-110,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：甘肃省科技厅“科技助力经济2020”重点项目(SQ2020YFF0404888)。

摘　　要：目的 评价宣肺止嗽合剂在临床“真实世界”治疗稳定期慢性阻塞性肺疾病(COPD)的疗效和安全性。方法 回顾性分析2021年7月—2021年11月国内8家医院的122例稳定期COPD患者的临床资料,统计服用宣肺止嗽合剂后症状体征(咽痛、咳嗽、咳痰、胸痛、咽痒、肺部啰音等),血常规[白细胞计数、中性粒细胞百分比、淋巴细胞百分比、C反应蛋白(CRP)]变化情况,记录不良事件。结果 患者治疗后发热、咽痛、咳嗽、咳痰、胸痛、咽痒、肺部啰音消失率分别为85.71%、50.94%、52.58%、38.46%、91.67%、37.84%,消失时间为分别为(7.25±3.90)d、(8.03±4.11)d、(8.09±5.32)d、(8.44±4.86)d、(7.07±5.21)d、(8.94±4.48)d。治疗后,患者白细胞计数、C反应蛋白含量较治疗前显著下降(P<0.05)。无不良反应发生。结论 宣肺止嗽合剂辅助治疗稳定期COPD相对安全且有较好疗效。Objective To evaluate the efficacy and safety of Xuanfei Zhisou Mixture(宣肺止嗽合剂)for stable chronic obstructive pulmonary disease(COPD)in real world when widely used.Methods From July 2021 to November 2021,the clinical data of 122 cases of stable COPD from eight hospitals in China was analyzed retrospectively.The changes of symptoms(pharyngeal pain,cough,expectoration,chest pain,itching in the throat and lung rales),blood test indexes[white blood cell count,percentage of neutrophils,percentage of lymphocyte and C reactive protein(CRP)]and the adverse reactions were recorded.Results The disappearance rates of sore throat,cough,cough up phlegm,chest pain,itchy throat and pulmonary rale was 85.71%,50.94%,52.58%,38.46%,91.67%and 37.84%,respectively,the disappearance timed was(7.25±3.90)d,(8.03±4.11)d,(8.09±5.32)d,(8.44±4.86)d,(7.07±5.21)d and(8.94±4.48)d,respectively.After treatment,leucocyte count and CRP decreased compared with those before treatment(P<0.05).There was no adverse reaction during the treatment.Conclusion Xuanfei Zhisou Mixture is relatively safe and effective for stable COPD when used auxiliarily.

关 键 词：宣肺止嗽合剂 稳定期慢性阻塞性肺疾病 真实世界 

分 类 号：R256[医药卫生—中医内科学]